Clinical Trial Update: Two Different Schedules of Palbociclib + Second Line Endocrine Therapy in Estrogen Receptor Positive, HER2 Neg Advanced/Metastatic Breast Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial studied two dosing schedules of palbociclib with second-line endocrine therapy for ER-positive, HER2-negative advanced/metastatic breast cancer.…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Palbociclib (palbociclib)

Snippet

Sponsor: Canadian Cancer Trials Group | Conditions: Breast Cancer | Phase 2 | Status: COMPLETED | Results posted: 2019-08-07